folding cage for cockfighting

folding cage for cockfighting

New Delhi: Tabla maestro Zakir Hussain has been admitted to the ICU of a San Francisco hospital with heart-related problems, his friend and flautist Rakesh Chaurasia said on Sunday. The 73-year-old US-based musician, who has taken the tabla to the global stage, had been having blood pressure issues, added Hussain’s manager Nirmala Bachani. “He has been admitted to a hospital in San Francisco for a heart-related problem for the last two weeks,” Bachani said. “He is unwell and admitted in the ICU right now. We all are worried about the situation,” Chaurasia told PTI. Amid reports claiming that Hussain had died, his publicist confirmed to PTI that the percussionist is being treated at the San Francisco hospital and “has not passed”. Hussain’s sister Khursheed told PTI that her brother is “very very critical” but is “very much breathing at the moment”. “My brother is deeply ill at this time. We are asking for all his fans around India and around the world to pray for him, to pray for his health. But as India’s greatest ever exports, do not finish him off just yet,” she said. “I just want to request all the media not to follow wrong information about Zakir’s passing. He is very much breathing at the moment. He is very very critical, but he’s still with us. He has not yet gone. So, I will request (the media) not to spread this rumour by writing or saying that he has passed away. I feel so bad watching all this information on Facebook which is very wrong,” she added. The eldest son of legendary tabla player Allah Rakha, Hussain has followed in the footsteps of his father, becoming a marquee name in India and across the world. Hussain has received five Grammy Awards in his career, including three at the 66th Grammy Awards earlier this year. In his career spanning six decades, the musician has worked with several renowned international and Indian artistes, but it was his 1973 musical project with English guitarist John McLaughlin, violinist L Shankar, and percussionist TH ‘Vikku’ Vinayakram that brought together Indian classical and elements of jazz in a fusion hitherto unknown. As concern mounted over Hussain’s health, senior broadcast journalist Pervaiz Alam also took to X to share the news, citing the musician’s brother-in-law Ayub Aulia. “Ustad Zakir Hussain, Tabla player, percussionist, composer, former actor and the son of legendary Tabla player, Ustad Allah Rakha is not well. He’s being treated for serious ailments in a San Francisco hospital, USA, informed his brother in law, Ayub Aulia in a phone call with me. Aulia sahab, based in London, has requested Zakir’s followers to pray for his speedy recovery,” he wrote in a post. The percussionist, one of India’s most celebrated classical muscians, received the Padma Shri in 1988, the Padma Bhushan in 2002, and the Padma Vibhushan in 2023.

Hormel Foods ( HRL 1.60% ) is a Dividend King offering a historically high 3.6% dividend yield. It appears to be on the sale rack right now, and a few years from now, long-term dividend investors will probably wish they had bought it. Here are four reasons why you should consider adding Hormel to your portfolio despite the headwinds it is facing today. 1. Hormel has an insider that thinks like you Companies answer to their investors. In theory, that should mean they make decisions that are in the best long-term interests of their investors. However, most companies know that their shares are owned by large institutions and asset management shops. So, the interests of small investors can often be overlooked. That's not likely to happen at Hormel. The Hormel Foundation controls roughly 46.8% of Hormel's stock. It was created by the founding family to ensure that Hormel would remain an independent company and support the local community in a philanthropic way. The stock control handles the first task; the dividends that Hormel pays are used to fund the second task. Or, to put it more simply, The Hormel Foundation wants Hormel, the food maker, to pay a sustainable and growing dividend over time. And Hormel, the food maker, has no choice but to listen because The Hormel Foundation is its largest shareholder. The best part of this, however, is that The Hormel Foundation's goal is likely to align with your own, assuming you are a conservative long-term dividend investor . 2. Hormel has a great track record Hormel is run for the long term, which is great. However, even better, Hormel's long-term success is really impressive. As noted, the company is a Dividend King . The dividend has been increased every single year for 58 consecutive years. That's not something that happens by accident; it requires a strong business model that is well executed over time. Given the involvement of The Hormel Foundation, it probably isn't shocking that Hormel is a Dividend King, but the proof of success is still nice to see. HRL data by YCharts 3. Every company goes through tough times That said, even the best companies in the world face periods where they underperform. That's just the normal business cycle at work. Clearly, Hormel has had to deal with some tough periods over the past 58 years. That span includes the raging inflation of the 1970s, the Dot.com bust, the Great Recession , and the COVID-19 pandemic, just to pick some notable highlights. It muddled through them all, with the exception of the pandemic impact, which is a lingering headwind right now. Given the history, though, there's no particular reason to believe Hormel won't muddle through again. 4. The list is long, but the problems are all manageable What is wrong today that has investors so worried about Hormel while the stock's yield is near historic highs? There's a list. The company has had a difficult time passing inflationary input costs on to consumers, the avian flu has been more difficult than usual, China's pandemic recovery has been slower than expected, and Hormel bought the Planters brand right when the nut segment of the snacking niche started to slow down. That is a long list, and it is understandable that investors are concerned. However, none of the issues is, individually, a company killer. Each one will either resolve itself or will be dealt with in time. The near-term impact of the collection, however, is weak financial results, which isn't good news. But Hormel isn't sitting around and waiting for better days. It is taking action. For example, cost-cutting efforts that had to be put on hold during the pandemic are now back up and running. The company is leaning into innovation to help boost demand in the U.S., China, and specifically for the Planters brand, which didn't see much innovation under the former owners. Notably, innovation is a key historical strength for Hormel. There's no reason to believe that this lever can't be used to reinvigorate consumer demand again. The real problem here is that solving the current slate of problems will take time, and Wall Street is looking for quick results. A quick recovery isn't in the cards at Hormel, but that's exactly why long-term dividend investors have the opportunity they have in front of them. If you can handle collecting a large yield while you wait for Hormel to muddle through another difficult period, then this stock could be a great addition to your income portfolio. Hormel is different today, but the goal is still the same To be fair, Hormel has changed over the last decade or so, going from a meat producer to a branded products company. So, this isn't the same business it was before. However, the goal of steady long-term business growth, supporting reliable dividend growth, hasn't changed. It is possible that Wall Street is reevaluating the stock and placing a lower valuation on the shares because of the changed business. Or it could just be investors thinking short-term, creating an investment opportunity for long-term income investors. The interesting thing is you can pretty much win either way. If this is a revaluation, then you are buying with a historically high yield that becomes the new normal yield. Hormel is still a well-run company that pays a large and reliable dividend. If investors are underestimating Hormel's ability to return to a faster growth path, then you will get a high yield and capital appreciation when Wall Street catches up to Hormel's improving performance.

EMPOLI, Italy (AP) — Englishman Keinan Davis scored with 14 minutes remaining for Udinese to draw at Empoli 1-1 in Serie A on Monday and snap the visitor's three-game losing streak. The former Watford and Aston Villa striker rose to head home a near-post corner with 76 minutes gone. Pietro Pellegri put Empoli ahead midway through the first half with his third goal in three games. The on-loan Torino striker has endured a lean season but a goal in the 1-0 win over Como was followed by another in the 1-1 draw with Lecce before the international break. The result was the first point in four games for Udinese, after consecutive defeats to Atalanta, Juventus and Venezia, and meant that both sides retained their mid-table positions. Udinese was ninth and Empoli 10th. Story continues below video Later, Venezia missed a chance to move off the foot of the table when it went down at home to Lecce 1-0. Venezia was dominant for most of the game, with Gaetano Oristanio and Jay Idzes hitting the woodwork and Wladimiro Falcone outstanding in the Lecce goal. But the home side paid for its profligacy after 70 minutes. Antonino Gallo’s sublime cross from the left was met by Patrick Dorgu at the far post and he steered the ball into the far corner to give Lecce all three points. Lecce, which started the night only two places above bottom side Venezia, jumped into 15th place. AP soccer: https://apnews.com/hub/soccer

Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development ProgramNo. 12 West Virginia women beat Boise State 82-47 to reach title game of Gulf Coast ShowcaseBOSTON--(BUSINESS WIRE)--Dec 10, 2024-- Skillsoft Corp. (NYSE: SKIL) (“Skillsoft” or the “Company”), a leading platform for transformative learning experiences, today announced its financial results for the third quarter of fiscal 2025 ended October 31, 2024. “Our fiscal third quarter financial results demonstrate our first step in executing our transformation strategy,” said Ron Hovsepian, Skillsoft’s Executive Chair and Chief Executive Officer. “The operationalization of our strategy is showing the first signs of business and financial improvement for our shareholders and customers.” “I am pleased with our financial results for the quarter, which are highlighted by strong revenue execution, improved profitability, and positive free cash flow,” said Rich Walker, Skillsoft’s Chief Financial Officer. “Our third quarter performance, coupled with momentum from our transformation execution, gives us confidence to raise and tighten our FY25 revenue guidance range, while reaffirming our adjusted EBITDA outlook.” The following table reflects Skillsoft’s updated financial outlook for the fiscal year ending January 31, 2025, based on current market conditions, expectations, and assumptions: GAAP Revenue $520 million – $530 million Adjusted EBITDA $105 million – $110 million (1) Growth calculated relative to the comparable prior year period unless otherwise noted. (2) See “Non-GAAP Financial Measures and Key Performance Metrics” below for the definitions of our key operational and non-GAAP metrics and how they are calculated and more information regarding the fact that the Company is unable to reconcile forward-looking non-GAAP measures without unreasonable efforts. We have provided at the back of this release reconciliations of our historical non-GAAP financial measures to the comparable GAAP measures. Skillsoft will host a conference call and webcast today at 5:00 p.m. Eastern Time to discuss its financial results. To access the call, dial (877) 413‐9278 from the United States and Canada or (215) 268‐9914 from international locations. The live event can be accessed from the Investor Relations section of Skillsoft’s website at . A replay will be available for six months. Skillsoft delivers transformative learning experiences that propel organizations and people to grow together. The Company partners with enterprise organizations and serves a global community of learners to prepare today’s employees for tomorrow’s economy. With Skillsoft, customers gain access to blended, multimodal learning experiences that do more than build skills, they grow a more capable, adaptive, and engaged workforce. Through a portfolio of high-quality content, an AI-enabled platform that is personalized and connected to customer needs, and a broad ecosystem of partners, Skillsoft drives continuous growth and performance for employees and their organizations by overcoming critical skills gaps, unlocking human potential, and transforming the workforce. Learn more at . The Company has organized its business into two segments (or Business Units): Talent Development Solutions (formerly referred to as Content & Platform) and Global Knowledge (formerly referred to as Instructor-Led Training). We track the non-GAAP financial measures and key performance metrics that we believe are key financial measures of our success. Non-GAAP measures and key performance metrics are frequently used by securities analysts, investors, and other interested parties in their evaluation of companies comparable to us, many of which present non-GAAP measures and key performance metrics when reporting their results. These measures can be useful in evaluating our performance against our peer companies because we believe the measures provide users with valuable insight into key components of U.S. GAAP financial disclosures. For example, a company with higher U.S. GAAP net income may not be as appealing to investors if its net income is more heavily comprised of gains on asset sales. Likewise, excluding the effects of interest income and expense moderates the impact of a company’s capital structure on its performance. However, non-GAAP measures and key performance metrics have limitations as analytical tools. Because not all companies use identical calculations, our presentation of non-GAAP financial measures and key performance metrics may not be comparable to other similarly titled measures of other companies. They are not presentations made in accordance with U.S. GAAP, are not measures of financial condition or liquidity, and should not be considered as an alternative to profit or loss for the period determined in accordance with U.S. GAAP or operating cash flows determined in accordance with U.S. GAAP. As a result, these performance measures should not be considered in isolation from, or as a substitute analysis for, results of operations as determined in accordance with U.S. GAAP. We have provided at the back of this press release reconciliations of our historical non-GAAP financial measures to the comparable GAAP measures. We do not reconcile our forward-looking non-GAAP financial measures to the corresponding U.S. GAAP measures, due to variability and difficulty in making accurate forecasts and projections and/or certain information not being ascertainable or accessible; and because not all of the information necessary for a quantitative reconciliation of these forward-looking non-GAAP financial measures to the most directly comparable U.S. GAAP financial measure is available to us without unreasonable efforts. For the same reasons, we are unable to address the probable significance of the unavailable information. We provide non-GAAP financial measures that we believe will be achieved, however we cannot accurately predict all of the components of the non-GAAP calculations and the U.S. GAAP measures may be materially different than the non-GAAP measures. We disclose the below non-GAAP financial measures and key performance metrics in this press release because we believe these non-GAAP financial measures and key performance metrics provide meaningful supplemental information. “ ” - For existing customers at the beginning of a given period, DRR represents subscription renewals, upgrades, churn, and downgrades in such period divided by the beginning total renewable base for such customers for such period. Renewals reflect customers who renew their subscription, inclusive of auto-renewals for multi-year contracts, while churn reflects customers who choose to not renew their subscription. Upgrades include orders from customers that purchase additional licenses or content (e.g., a new Leadership and Business module), while downgrades reflect customers electing to decrease the number of licenses or reduce the size of their content package. Upgrades and downgrades also reflect changes in pricing. We use our DRR to measure the long-term value of customer contracts as well as our ability to retain and expand the revenue generated from our existing customers. - Adjusted net income (loss) is defined as GAAP net income (loss) excluding non-cash items, discrete and event-specific costs that do not represent normal, recurring, cash operating expenses necessary for our business operations, and certain accounting income and/or expenses that management believes are necessary to enhance the comparability and are useful in assessing our operating performance, include the following (including the related tax effects): - Adjusted EBITDA is defined as adjusted net income (loss) excluding interest expense or income, benefit from or provision for income taxes, depreciation and amortization expense. – Adjusted operating expenses are defined as GAAP costs of revenues, content and software development, selling and marketing, and general and administrative expenses, excluding depreciation expense, long-term incentive compensation expense, system migration costs, transformation costs, and other non-cash charges, as applicable. – Adjusted gross margin is defined as GAAP revenue less GAAP cost of revenues, excluding long-term incentive compensation expense and depreciation expense, divided by GAAP revenue for the same period. – Adjusted contribution margin is defined as GAAP revenue less adjusted operating expenses, divided by GAAP revenue for the same period. – Free cash flow is defined as GAAP net cash provided by (used in) operating activities less purchases of property and equipment and internally developed software. – Adjusted free cash flow (levered) is defined as free cash flow plus the cash impact for adjusted EBITDA excluded charges. – Free cash flow conversion is defined as free cash flow divided by adjusted EBITDA for the same period. – Net leverage is defined as current maturities of long-term debt, plus borrowings under accounts receivable facility, plus long-term debt, less cash and equivalents and restricted cash, divided by adjusted EBITDA for the preceding twelve-month period. Certain amounts reported in prior years have been reclassified to conform to the presentation in the current year. These reclassifications had no effect on total assets, total liabilities, total stockholders' equity, or net income (loss) for the prior year. This document includes statements that are, or may be deemed to be, “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created by those laws. All statements, other than statements of historical facts, that address activities, events or developments that we expect or anticipate may occur in the future, including such things as our outlook (including revenue, non-GAAP EBITDA, and free cash flow), our product development and planning, our sales pipeline, future capital expenditures, share repurchases, financial results, the impact of regulatory changes, existing and evolving business strategies and acquisitions and dispositions, demand for our services, competitive strengths, the benefits of new initiatives, growth of our business and operations, and our ability to successfully implement our plans, strategies, objectives, expectations and intentions are forward-looking statements. Also, when we use words such as “may”, “will”, “would”, “anticipate”, “believe”, “estimate”, “expect”, “intend”, “plan”, “project”, “forecast”, “seek”, “outlook”, “target”, “goal”, “probably”, or similar expressions, we are making forward-looking statements. Such statements are based upon the current beliefs and expectations of Skillsoft’s management and are subject to significant risks and uncertainties. All forward-looking disclosure is speculative by its nature, and we caution you against unduly relying on these forward-looking statements. Factors that could cause or contribute to such differences include those described under “Part I - Item 1A. Risk Factors” in our Form 10‐K for the fiscal year ended January 31, 2024. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements included in our other periodic filings with the Securities and Exchange Commission. The forward-looking statements contained in this document represent our estimates only as of the date of this filing and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so, whether to reflect actual results, changes in assumptions, changes in other factors affecting such forward-looking statements, or otherwise. Although we believe that the assumptions underlying our forward-looking statements are reasonable, any of these assumptions, and therefore also the forward-looking statements based on these assumptions, could themselves prove to be inaccurate. Given the significant uncertainties inherent in the forward-looking statements included in this document, our inclusion of this information is not a representation or guarantee by us that our objectives and plans will be achieved. Annualized, pro forma, projected and estimated numbers are used for illustrative purposes only, are not forecasts and may not reflect actual results. Additionally, statements as to market share, industry data and our market position are based on the most current data available to us and our estimates regarding market position or other industry data included in this document or otherwise discussed by us involve risks and uncertainties and are subject to change based on various factors, including as set forth above. (in thousands, except number of shares and per share amounts) Current assets: Cash and cash equivalents $ 97,921 $ 136,308 Restricted cash 3,881 10,215 Accounts receivable, net of allowance for credit losses of approximately $558 and $562 as of October 31, 2024 and January 31, 2024, respectively 102,498 185,638 Prepaid expenses and other current assets 55,834 53,170 Total current assets 260,134 385,331 Property and equipment, net 3,543 6,639 Goodwill 317,071 317,071 Intangible assets, net 456,692 539,293 Right of use assets 5,054 8,044 Other assets 11,037 17,256 Total assets $ 1,053,531 $ 1,273,634 Current liabilities: Current maturities of long-term debt $ 6,404 $ 6,404 Borrowings under accounts receivable facility 10,009 44,980 Accounts payable 21,159 14,512 Accrued compensation 28,325 31,774 Accrued expenses and other current liabilities 22,370 29,939 Lease liabilities 2,088 3,049 Deferred revenue 203,646 282,570 Total current liabilities 294,001 413,228 Long-term debt 574,312 577,487 Deferred tax liabilities 44,099 52,148 Long-term lease liabilities 6,839 9,251 Deferred revenue - non-current 1,823 2,402 Other long-term liabilities 11,977 13,531 Total long-term liabilities 639,050 654,819 Commitments and contingencies Shareholders’ equity: Shareholders’ common stock - Class A common shares, $0.0001 par value: 18,750,000 shares authorized and 8,576,683 shares issued and 8,276,906 shares outstanding at October 31, 2024, and 8,380,436 shares issued and 8,080,659 shares outstanding at January 31, 2024 1 1 Additional paid-in capital 1,559,547 1,551,005 Accumulated equity (deficit) (1,412,279 ) (1,321,478 ) Treasury stock, at cost - 299,777 shares as of October 31, 2024 and January 31, 2024 (10,891 ) (10,891 ) Accumulated other comprehensive income (loss) (15,898 ) (13,050 ) Total shareholders’ equity 120,480 205,587 Total liabilities and shareholders’ equity $ 1,053,531 $ 1,273,634 (in thousands, except per share amounts) Revenues: Total revenues $ 137,225 $ 138,956 $ 397,241 $ 415,697 Operating expenses: Costs of revenues 34,312 36,407 101,254 114,698 Content and software development 14,937 16,126 45,436 51,024 Selling and marketing 39,615 43,983 122,591 130,321 General and administrative 21,686 22,308 66,390 72,689 Amortization of intangible assets 31,826 38,620 95,197 116,086 Acquisition and integration related costs 931 510 3,349 2,838 Restructuring 3,095 873 15,361 8,592 Total operating expenses 146,402 158,827 449,578 496,248 Operating income (loss) (9,177 ) (19,871 ) (52,337 ) (80,551 ) Other income (expense), net (538 ) 19 1,261 (1,290 ) Fair value adjustment of warrants — 1,105 — 4,750 Fair value adjustment of interest rate swaps (822 ) 3,981 418 11,186 Interest income 924 1,060 2,897 2,576 Interest expense (15,845 ) (16,492 ) (48,538 ) (48,683 ) Income (loss) before provision for (benefit from) income taxes (25,458 ) (30,198 ) (96,299 ) (112,012 ) Provision for (benefit from) income taxes (1,859 ) (2,462 ) (5,498 ) (8,735 ) Income (loss) from continuing operations (23,599 ) (27,736 ) (90,801 ) (103,277 ) Gain (loss) on sale of business — — — (682 ) Net income (loss) $ (23,599 ) $ (27,736 ) $ (90,801 ) $ (103,959 ) Net income (loss) per share: Basic and diluted - continuing operations $ (2.86 ) $ (3.45 ) $ (11.11 ) $ (12.84 ) Basic and diluted - discontinued operations — — — (0.08 ) Basic and diluted $ (2.86 ) $ (3.45 ) $ (11.11 ) $ (12.92 ) Weighted average common shares outstanding: Basic and diluted 8,239,564 8,047,497 8,170,344 8,043,712 (in thousands) Cash flows from operating activities: Net income (loss) $ (90,801 ) $ (103,959 ) Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: Amortization of intangible assets 95,197 116,086 Stock-based compensation 9,985 22,917 Depreciation 2,404 2,629 Non-cash interest expense 1,628 1,546 Non-cash property, equipment, software and lease impairment charges 2,495 4,265 Provision for credit loss expense (recovery) (4 ) 205 (Gain) loss on sale of business — 682 Provision for (benefit from) deferred income taxes – non-cash (8,080 ) (10,270 ) Fair value adjustment of warrants — (4,750 ) Fair value adjustment of interest rate swaps (418 ) (11,186 ) Change in assets and liabilities: Accounts receivable 82,877 70,645 Prepaid expenses and other assets, including long-term 4,258 2,726 Right-of-use assets 1,632 2,184 Accounts payable 6,693 (3,283 ) Accrued expenses and other liabilities, including long-term (12,819 ) (20,820 ) Lease liabilities (3,387 ) (3,048 ) Deferred revenues (79,446 ) (75,250 ) Net cash provided by (used in) operating activities 12,214 (8,681 ) Cash flows from investing activities: Purchase of property and equipment (820 ) (3,753 ) Proceeds from sale of property and equipment 10 — Internally developed software - capitalized costs (13,018 ) (8,055 ) Sale of SumTotal, net of cash transferred — (5,137 ) Net cash provided by (used in) investing activities (13,828 ) (16,945 ) Cash flows from financing activities: Shares repurchased for tax withholding upon vesting of restricted stock-based awards (1,052 ) (1,441 ) Payments to acquire treasury stock — (8,046 ) Proceeds from (payments on) accounts receivable facility (34,971 ) 793 Principal payments on term loans (4,803 ) (4,803 ) Net cash provided by (used in) financing activities (40,826 ) (13,497 ) Effect of exchange rate changes on cash and cash equivalents (2,281 ) (1,674 ) Net increase (decrease) in cash, cash equivalents and restricted cash (44,721 ) (40,797 ) Cash, cash equivalents and restricted cash, beginning of period 146,523 177,556 Cash, cash equivalents and restricted cash, end of period $ 101,802 $ 136,759 Supplemental disclosure of cash flow information: Cash and cash equivalents $ 97,921 $ 129,806 Restricted cash 3,881 6,953 Cash, cash equivalents and restricted cash, end of period $ 101,802 $ 136,759 (in thousands, unaudited) Talent Development Solutions $ 102,998 $ 101,132 $ 302,725 $ 302,893 Global Knowledge 34,227 37,824 94,516 112,804 $ $ $ $ $ $ $ $ Acquisition and integration related costs 931 510 3,349 2,838 Restructuring 3,095 873 15,361 8,592 Transformation costs 164 1,053 1,351 2,503 System migration costs — 510 118 1,580 Long-term incentive compensation expenses 4,099 7,962 10,438 22,917 Executive exit costs — — 3,326 — Fair value adjustment of warrants — (1,105 ) — (4,750 ) Fair value adjustment of interest rate swaps 822 (3,981 ) (418 ) (11,186 ) Foreign currency impact 524 (181 ) (1,297 ) 1,513 Gain (loss) on sale of business — — — 682 Tax impact of adjustments (1,057 ) (602 ) (3,349 ) (2,921 ) Interest expense, net 14,921 15,432 45,641 46,107 Expense (benefit from) income taxes, excluding tax impacts above (802 ) (1,860 ) (2,149 ) (5,814 ) Depreciation 1,000 266 2,404 2,629 Amortization of intangible assets 31,826 38,620 95,197 116,086 $ $ $ $ Weighted average common shares outstanding: Basic and diluted 8,239,564 8,047,497 8,170,344 8,043,712 Basic and diluted per share information: Net income (loss), as reported $ (2.86 ) $ (3.45 ) $ (11.11 ) (12.92 ) Adjusted net income (loss) from continuing operations $ (1.82 ) $ (2.82 ) $ (7.58 ) $ (10.22 ) Interest expense, net 10.9 % 11.1 % 11.5 % 11.1 % Expense (benefit from) income taxes, excluding tax impacts above (0.6 )% (1.3 )% (0.5 )% (1.4 )% Depreciation 0.7 % 0.2 % 0.6 % 0.6 % Amortization of intangible assets 23.2 % 27.8 % 23.9 % 27.9 % (in thousands, unaudited) Operating expenses: GAAP costs of revenues $ 34,312 $ 36,407 $ 101,254 $ 114,698 Depreciation (91 ) (80 ) (315 ) (413 ) Long-term incentive compensation expenses (201 ) (128 ) (499 ) (463 ) Adjusted costs of revenues 34,020 36,199 100,440 113,822 GAAP content and software development 14,937 16,126 45,436 51,024 Depreciation (74 ) 22 (218 ) (169 ) Long-term incentive compensation expenses (857 ) (1,575 ) (3,061 ) (5,350 ) System migration — (510 ) (118 ) (1,580 ) Adjusted content and software development 14,006 14,063 42,039 43,925 GAAP selling and marketing 39,615 43,983 122,591 130,321 Depreciation (161 ) (160 ) (531 ) (839 ) Long-term incentive compensation expenses (1,595 ) (1,421 ) (3,648 ) (2,435 ) Transformation — (9 ) (213 ) (251 ) Adjusted selling and marketing 37,859 42,393 118,199 126,796 GAAP general and administrative 21,686 22,308 66,390 72,689 Depreciation (674 ) (48 ) (1,340 ) (1,208 ) Long-term incentive compensation expenses (1,446 ) (4,838 ) (3,230 ) (14,669 ) Transformation (179 ) (882 ) (1,192 ) (2,475 ) Executive exit costs — — (3,326 ) — Adjusted general and administrative 19,387 16,540 57,302 54,337 Total GAAP operating expenses 110,550 118,824 335,671 368,732 Depreciation (1,000 ) (266 ) (2,404 ) (2,629 ) Long-term incentive compensation expenses (4,099 ) (7,962 ) (10,438 ) (22,917 ) System migration — (510 ) (118 ) (1,580 ) Transformation (1) (179 ) (891 ) (1,405 ) (2,726 ) Executive exit costs — — (3,326 ) — Adjusted total operating expenses $ 105,272 $ 109,195 $ 317,980 $ 338,880 (1) This line item does not agree to the amounts reflected on preceding table due to certain transformation expenses not being reflected in GAAP operating expenses. (in thousands) Net cash provided by (used in) operating activities $ 8,717 $ (10,666 ) $ 12,214 $ (8,681 ) Purchase of property and equipment, net (411 ) (347 ) (810 ) (3,753 ) Internally developed software - capitalized costs (4,222 ) (2,104 ) (13,018 ) (8,055 ) Total free cash flow Cash impact for adjusted EBITDA excluded charges 10,089 2,306 17,187 10,098 Adjusted free cash flow (levered) $ $ $ $ ) View source version on : CONTACT: Investors: Ross Collins or Stephen Poe : Cameron Martin KEYWORD: MASSACHUSETTS UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: TECHNOLOGY SECURITY OTHER TECHNOLOGY SOFTWARE INTERNET CONTINUING TRAINING DATA MANAGEMENT EDUCATION SOURCE: Skillsoft Corp. Copyright Business Wire 2024. PUB: 12/10/2024 04:05 PM/DISC: 12/10/2024 04:04 PM

Kylian Mbappé created history as Real Madrid went to Bergamo for the Matchday 6 tie in the 2024-25 UEFA Champions League. He scored the first goal within the first half of the match, sending his team into a crucial win while breaking Cristiano Ronaldo’s all-time goalscoring record in the process. The game ended with 2-3, favoring Real Madrid. Mbappé’s switch to Real Madrid this summer season had created much hype, although he had a rather muted start to the season. However, in the recent games, the 25-year-old forward has started to get his rhythm going, especially in the Champions League. Finding the back of the net in successive games, the goal against Atalanta was Mbappé’s 12th for the team since his arrival. His strike in the first ten minutes of the game against Atalanta was not only a match-winner but also a milestone moment when he broke Ronaldo’s record of scoring the most goals in the Champions League for a long time. Mbappé has scored 50 goals in just 79 games, which is the quickest time to reach the mark. It took Ronaldo 91 games to do it. Mbappé Beats Legends Mbappé is thus placed in elite company. Not only did he surpass Ronaldo but managed to surpass several other footballing legends on the all-time list, including Raul González, Thierry Henry, Thomas Müller, and Karim Benzema. Mbappé now stands at four with 50 goals at just 79 games with the record book showing some of the quickest players that have achieved this feat, Robert Lewandowski having hit it at 77, Lionel Messi at 66, and Ruud van Nistelrooy at 62. The French forward started his journey in the Champions League back in the 2016-17 season with Monaco, scoring six goals in his debut season. Then he moved to Paris Saint-Germain, where his tally grew significantly as he scored 42 goals between 2017 and 2024. Now with Real Madrid, Mbappé has already made his mark in the competition with two goals in just a short period at the Spanish club. Mbappé Among Youngest Players To Score 50 Goals At the tender age of 25 years and 356 days, Mbappé is one of the youngest players to ever have reached 50 Champions League goals. The only player younger than him is Lionel Messi , who achieved the same at 24 years and 284 days. Considering the fact that he reached this milestone in fewer games than most of the stars who compete with him makes the achievement even more significant. This is a landmark achievement which cements Mbappé into the ranks of the brightest stars in European football. As he continues to grow and evolve at Real Madrid, the question now is how many more records he will break before his career is over. The 100-Goal Club With such a stellar scoring rate, Mbappé is now on course to achieving another glorious mark: 100 Champions League goals. At the moment, he will certainly equal football’s all-time greats if he continues at the rate he is going; they include Cristiano Ronaldo, 145 goals; Lionel Messi, 132; and Robert Lewandowski, 109. Currently 25 years of age, Mbappé is indeed on course to become one of the most prolific goal-scorers in this competition. Mbappé, as long as he shines in the Champions League both for Real Madrid and the international arena, seems to have an incredibly bright future. Every goal brings him closer to the pantheon of all-time football players. ALSO READ | Vinicius Jr And Rodrygo Return For Real Madrid’s Champions League Clash Against Atalanta‘Really disgusting’: Surgeons probed over ‘operating on multiple TAC patients at same time’

Proposed acquisition strengthens Pharming’s late-stage pipeline with a potential first-in-disease asset Abliva’s lead product KL1333 is currently in a pivotal clinical trial, with a positive interim analysis achieved, in mitochondrial DNA-driven primary mitochondrial diseases Total transaction value of approximately US$66.1 million No external funding required to fund acquisition and KL1333 development costs Pharming to host a conference call on Monday, December 16, 2024 at 14:00 CET (8:00 am EST) Leiden, the Netherlands, December 15, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) today announced a recommended public cash offer to the shareholders of Abliva AB (“Abliva”) to acquire all issued and outstanding shares of Abliva. Pharming, through its wholly-owned subsidiary Pharming Technologies B.V., offers the shareholders SEK 0.45 in cash per share in Abliva. The transaction is valued at approximately US$66.1 million. Abliva is a biotechnology company, based in Lund, Sweden, focused on developing medicines for the treatment of mitochondrial disease. Abliva’s lead product, KL1333, a regulator of the essential co-enzymes NAD+ and NADH, is in a pivotal clinical study (FALCON) in adult patients with genetically confirmed primary mitochondrial disease (PMD) with mitochondrial DNA (mtDNA) mutations who experience consistent, debilitating fatigue and muscle weakness (myopathy), and reduced life expectancy. Over 30,000 patients diagnosed with mtDNA mitochondrial disease would be potentially addressable by KL1333 in the U.S., EU4 (France, Germany, Italy, Spain) and the UK. KL1333 has shown positive clinical effects in a proof-of-concept Phase 1b study, and a pre-planned interim analysis of the ongoing pivotal FALCON trial demonstrated promising differences over placebo in both alternate primary efficacy endpoints. KL1333 has received Fast Track designation in the U.S. and Orphan Drug Designation for the treatment of PMD in the U.S. and EU. Sijmen de Vries, Chief Executive Officer of Pharming, said: “Abliva has made exciting progress developing KL1333, a potential first-in-disease treatment undergoing a pivotal clinical trial that offers new hope to patients with rare mtDNA mitochondrial disease who experience debilitating fatigue and muscle weakness. With over 30,000 addressable patients in the U.S., EU4 and UK, we are excited about the potential of this asset, which achieved a positive interim analysis in the registration trial in July 2024. We believe KL1333 has blockbuster potential in the U.S. alone and can significantly change Pharming’s future growth trajectory. We will fund this acquisition using existing cash, and anticipate covering costs to complete the pivotal trial with positive cash flows from our existing business. The acquisition of Abliva would further strengthen our clinical pipeline with the addition of a therapy, with U.S. launch expected in 2028, aligning with our vision to become a leading global rare disease company. We are pleased that Abliva’s independent Board of Directors and major shareholders recognize the expertise and value Pharming brings to the development and eventual commercialization of KL1333, and unanimously support this transaction. We look forward to welcoming the Abliva team with their strong expertise in mitochondrial research and drug development and to combining with our resources, capabilities and commercial infrastructure to bring this groundbreaking and important medicine to patients and their healthcare providers.” Transaction highlights Today at 19:45 CET, Pharming announced a recommended cash offer to the shareholders of Abliva AB. Hereby Pharming, through a wholly owned subsidiary, has offered SEK 0.45 in cash for each outstanding share of Abliva (the ''Offer''). The total value of the Offer based on all outstanding 1,611,884,536 shares in Abliva amounts to approximately SEK 725,348,041, or approximately US$66.1 million. The Board of Directors of Abliva unanimously recommends the shareholders of Abliva to accept the Offer. The Board of Directors of Abliva has obtained a fairness opinion from PwC, according to which, based on the assumptions and reservations stated in the opinion, the Offer is fair to Abliva’s shareholders from a financial perspective. Pharming has obtained acceptance undertakings from the three largest shareholders, accounting for 49.82% of Abliva's outstanding shares. The Offer is subject to customary regulatory approvals, and Pharming expects to obtain such approvals prior to the end of the acceptance period. Pharming Group N.V. has cash on hand to finance the Offer in full. The acceptance period in the offer is expected to commence on or around January 16, 2025 and to expire on or around February 7, 2025. For information in relation to the Offer, please refer to www.raredisease-offer.com. An offer document will be made public by Pharming shortly before the commencement of the acceptance period. Van Lanschot Kempen N.V. is sole financial advisor and NautaDutilh N.V. and Mannheimer Swartling Advokatbyrå are legal advisors to Pharming in connection with the Offer. Invitation to conference call Pharming to host a conference call on Monday, December 16, 2024, at 14:00 CET (8:00 am EST). The conference call presentation is available on the pharming.com website from 14:00 CET on December 16, 2024 A transcript will be made available on the pharming.com website in the days following the call. To participate in the conference call, please register in advance using the link below. Once registered, dial-in information and a unique PIN will be provided, allowing access to the call. Conference call dial-in details: Please note, the Company will only take questions from dial-in attendees. https://register.vevent.com/register/BIfcd1fd2bdf0e443cbf6192dc063763ad Webcast Link: https://edge.media-server.com/mmc/p/2hfpccyi For further public information, contact: Pharming Group, Leiden, the Netherlands Michael Levitan, VP Investor Relations & Corporate Communications T: +1 (908) 705 1696 E: investor@pharming.com FTI Consulting, London, UK Victoria Foster Mitchell/Alex Shaw/Amy Byrne T: +44 203 727 1000 LifeSpring Life Sciences Communication, Amsterdam, the Netherlands Leon Melens T: +31 6 53 81 64 27 E: pharming@lifespring.nl Abliva investors Leo Wei T: +46 (0)709 910 081 E: pharming@fogelpartners.se About KL1333 KL1333 has been designed to treat chronic fatigue and myopathy (muscle weakness) in genetically confirmed adult patients with primary mitochondrial disease. Diagnoses can include MELAS-MIDD and KSS-CPEO spectrum disorders as well as MERRF syndrome. The drug candidate is intended for long-term oral treatment. KL1333 has the ability to restore the ratio of NAD+ and NADH, and thus leads to the formation of new mitochondria and improved energy levels. In a cohort of mitochondrial disease patients in a Phase 1a/b study, the patients who received KL1333 showed both improvements in symptoms of fatigue as well as functional improvements. KL1333 is currently being evaluated in a global, potentially registrational, Phase 2 study (the FALCON study) and has received orphan drug designation in both the USA and Europe as well as Fast Track designation in the USA. About the FALCON Study FALCON is a Phase 2, global, randomized, placebo-controlled, potentially registrational study evaluating the safety and efficacy of KL1333 in adult patients with primary mitochondrial disease who experience consistent, debilitating fatigue and myopathy (muscle weakness), the most common and impairing symptoms. A total of 180 patients with mitochondrial DNA mutations who meet the eligibility criteria are randomized 3:2 to receive KL1333 (50mg-100mg) or placebo twice daily for 48 weeks. The two alternative primary endpoints assess consistent fatigue (using the PROMIS® Fatigue Mitochondrial Disease Short Form) and myopathy (using the 30 second Sit-to-Stand test), only one of which must be positive to file for marketing approval. An interim analysis evaluating 24-week data from the first wave of patients confirmed the strong safety profile of KL1333, and both primary endpoints passed futility, meaning that both have the potential to demonstrate benefit in the final analysis of the study. About Abliva AB Abliva discovers and develops medicines for the treatment of mitochondrial disease. This rare and often very severe disease occurs when the cell’s energy provider, the mitochondria, do not function properly. The company has prioritized two projects. KL1333, a powerful regulator of the essential co-enzymes NAD+ and NADH, has entered late-stage development. NV354, an energy replacement therapy, has completed preclinical development. Abliva, based in Lund, Sweden, is listed on Nasdaq Stockholm, Sweden (ticker: ABLI). For more information, please visit www.abliva.com. About Pharming Group N.V. Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific. For more information, visit www.pharming.com and find us on LinkedIn . Forward-Looking Statements This press release may contain forward-looking statements. Forward-looking statements are statements of future expectations that are based on management’s current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in these statements. These forward-looking statements are identified by their use of terms and phrases such as “aim”, “ambition”, ‘‘anticipate’’, ‘‘believe’’, ‘‘could’’, ‘‘estimate’’, ‘‘expect’’, ‘‘goals’’, ‘‘intend’’, ‘‘may’’, “milestones”, ‘‘objectives’’, ‘‘outlook’’, ‘‘plan’’, ‘‘probably’’, ‘‘project’’, ‘‘risks’’, “schedule”, ‘‘seek’’, ‘‘should’’, ‘‘target’’, ‘‘will’’ and similar terms and phrases. Examples of forward-looking statements may include statements with respect to timing and progress of Pharming's preclinical studies and clinical trials of its product candidates, Pharming's clinical and commercial prospects, and Pharming's expectations regarding its projected working capital requirements and cash resources, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to the scope, progress and expansion of Pharming's clinical trials and ramifications for the cost thereof; and clinical, scientific, regulatory, commercial, competitive and technical developments. In light of these risks and uncertainties, and other risks and uncertainties that are described in Pharming's 2023 Annual Report and the Annual Report on Form 20-F for the year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission, the events and circumstances discussed in such forward-looking statements may not occur, and Pharming's actual results could differ materially and adversely from those anticipated or implied thereby. All forward-looking statements contained in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Readers should not place undue reliance on forward-looking statements. Any forward-looking statements speak only as of the date of this press release and are based on information available to Pharming as of the date of this release. Pharming does not undertake any obligation to publicly update or revise any forward-looking statement as a result of new information, future events or other information. Inside Information This press release relates to the disclosure of information that qualifies, or may have qualified, as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. Attachment Pharming announces public cash offer to the shareholders of Abliva AB_EN_15DEC24

TORONTO, Nov. 25, 2024 (GLOBE NEWSWIRE) — Hitachi Rail is proud to partner with Invest Ontario as part of a more than C$100 million investment to upgrade its world-leading Communication-Based Train Control (CBTC) signalling technology. Hitachi Rail aims to develop a new generation of its CBTC technology, SelTracTM (G9), which will integrate artificial intelligence (AI), 5G communications, edge and cloud computing. The next generation system will offer transit operators worldwide lower costs, minimized carbon footprint and enhanced passenger experience. The investment includes the expansion of Hitachi Rail’s workforce in Toronto, Ontario, creating 100 new jobs and retaining 1,000 highly skilled positions in its York Mills office, including R&D and engineering roles. “The over $100 million investment in the next generation of our world-leading SelTracTM technology is hugely exciting – and we are grateful to the Government of Ontario and Invest Ontario for their support,” said . “By integrating AI, 5G, edge and cloud computing, our system will allow urban rail transportation operators around the globe to improve passenger journeys and operate more efficiently. This Ontario-invented technology is a Canadian success story that is creating jobs and boosting economic growth.” CBTC is a modern urban signalling system that uses wireless communication between trains and infrastructure to operate urban transit and subway systems more efficiently and safely than conventional signalling. SelTracTM, invented in Ontario, is the world’s first moving block CBTC signalling system, currently operating in more than 100 lines in 40 major cities around the world including the O-Train in Ottawa. Ontario, home to one of the largest tech clusters in North America, is renowned for its strength in AI, automation and connectivity technologies. The province’s expertise in smart mobility, combined with Hitachi Rail’s global competence centre, makes Ontario the natural place to develop next-generation digital solutions for urban rail and metros. “As one of the largest and most sought-after tech hubs in North America, Ontario is driving the development of next-generation technologies that will strengthen economic growth across key sectors, including automation and transportation,” said . “Through Invest Ontario, we are proud to support Hitachi Rail’s expansion in Toronto and thank them for choosing our province as the ideal place for their continued growth and success.” The company’s York Mills office in Toronto serves as its engineering centre of excellence, equipped with state-of-the-art facilities including labs, testing areas, and simulation environments. This expansion adds to Hitachi Rail’s growing presence in Canada that includes around 1,200 employees across the country, who are delivering and maintaining major transit projects in Toronto, Vancouver, Montreal and Ottawa. Toronto is home to the company’s international urban transit signalling technology business, as well as large program teams based downtown and Mississauga that are delivering major new transit infrastructure, like the Ontario Line and Hurontario. “Under the leadership of Premier Ford, our government is investing $70 billion in the largest transit expansion in North America, connecting millions more Ontarians to reliable and affordable public transit. Today’s announcement means Hitachi Rail will be helping even more workers gain the critical expertise needed to deliver Ontario’s generational projects,” said . “Hitachi Rail’s investment is a testament to Ontario’s strengths in future technologies that are transforming industries from manufacturing to transportation. We are excited to support the company in advancing a made-in-Ontario technology that keeps cities around the world on the move,” said . In support of this investment, Ontario is providing $4.5 million in funding through the . Contact: Adam Love, Hitachi Rail on +1 (437) 234 4024, Notes to the editors: Hitachi Rail invented moving block CBTC technology in 1974 in Toronto with the support of the Ontario government. Since then, it has evolved into the world’s leading technology for urban rail and transit systems. The investment in G9 coincides with the 50 anniversary of the invention of the original technology. We have deployed CBTC technology in Ottawa, Montreal, London, Hong Kong, Doha, New York, Chile, Malaysia, Saudi Arabia, Turkey and the UAE in the past 10 years. Hitachi Rail is committed to driving the sustainable mobility transition and has a clear focus on partnering with customers to rethink mobility. Its mission is to help every passenger, customer and community enjoy the benefits of more connected, seamless and sustainable transport. With revenues of over €7bn and 24,000 employees across more than 50 countries, Hitachi Rail is a trusted partner to the world’s best transport organisations. The company’s reach is global, but the business is local – with success built on developing local talent and investing in people and communities. Its international capabilities and expertise span every part of the urban, mainline and freight rail ecosystems – from high quality manufacturing and maintenance of rolling stock to secure digital signalling, smart operations and payment systems. Hitachi Rail, famous for Japan’s iconic high speed bullet train, draws on the digital and AI expertise of Hitachi Group companies to accelerate innovation and develop new technologies. Hitachi Group is present in 140 countries with over 270,000 employees and global revenues of €54.55bn / ¥8,564 bn. For more information, visit . A photo accompanying this announcement is available atAfter topping electric cars, Chinese firms set eyes on challenges in EV truck market

Purdue athletic director Mike Bobinski promised to give new coach Barry Odom everything he needed to revive the Boilermakers program. Increasing the NIL budget is a solid start. Odom knows what's coming next — the questions. So naturally, it didn't take long for the former UNLV coach to be asked one thing he's likely to hear frequently on the recruiting trail: Could he explain the payment dispute that led to the departure of his starting quarterback, Matthew Sluka, after just three games this season? “I think every story, you look at what you're able to say, what's the truth, what's the reality and what's fabricated,” Odom said Tuesday at his introductory news conference. “I think you look at that very specific instance there was very open communication from the day the recruiting process started. Everything we did as a staff, as a university, as an athletic department was by the book and by the law.” Sluka transferred from Holy Cross to UNLV after twice being selected as a Walter Payton Award finalist. The award goes to the best player in the Football Championship Series. He didn't last long in Las Vegas. Sluka entered the transfer portal after winning all three starts, claiming he never received a promised $100,000 NIL payment. Odom issued a statement at the time saying the program abided by the “applicable rules.” On Tuesday, he seemed to acknowledge that part of the explanation was a continuing quarterback competition between Sluka and Hajj Malik-Williams, who took over as the starter and led UNLV (10-3) to its best record in 40 years and a second straight Mountain West Conference championship game appearance. Malik-Williams was a second-team all-conference selection. Odom likely will need more detailed answers for prospective recruits if he intends to make the Boilermakers competitive again in a Big Ten with four playoff-bound teams. Odom does have some advantages at Purdue — a strong alumni base led by former NFL star Drew Brees, a recently renovated stadium, other upgraded facilities and the school's longtime reputation as the “Cradle of Quarterbacks.” The biggest advantage, though, will be Purdue going all in on NIL money. “We’re going to operate at the full cap," Bobinski said. “We’re going to be as resourced as anybody in the country, allowing Barry and his staff the ability to go out there and be eyeball to eyeball with everybody we’re competing for, a transfer or from a high school recruiting perspective.” Bobinski said Odom's results at UNLV were the primary attraction, though. As the Boilermakers continued to struggle in November, Bobinski started studying the revival of a UNLV program that had struggled for decades. What he found was that the man Missouri fired in 2019 after posting a 25-25 record in four seasons had earned a second chance with a Power Four program. “What was accomplished at UNLV these last couple years was nothing short of remarkable,” Bobinski said. “What that shows me is Coach Odom brings a very unique combination of an old-school, traditional football toughness and mindset with ability to operate and adapt to today’s college football environment.” It's a combination Purdue desperately needs following an embarrassing 2024 season in which it went 1-11 (0-9 Big Ten) and suffered the two most lopsided losses in school history — 66-7 to Notre Dame and 66-0 to Indiana. He takes over a team that lost its final 11 games and did not beat an FBS opponent. Navigating the path back in what's likely to be the first year of revenue sharing and NIL caps tied to roster limits could be even trickier given what he's facing. The state's other two most prominent programs — No. 3 Notre Dame (11-1, No. 5 CFP) and No. 9 Indiana (11-1, No. 8 CFP), will meet in a first-round playoff game on Dec. 20. There are other complications, too. Purdue signed only six recruits on the first day of the early signing period and has 21 players currently in the transfer portal, including All-American safety Dillon Thieneman, starting linebacker Yanni Karlaftis, starting tight end Max Klare and two quarterbacks. “We've got to be great evaluators, and then you've got to build an offense or a defense and a kicking game around the strengths of our players,” Odom said. “And then we've got to be great teachers at making them and teaching them, understanding the reasons we're calling the play and how important their job is to get that job done.” Get poll alerts and updates on the AP Top 25 throughout the season. Sign up here . AP college football: https://apnews.com/hub/ap-top-25-college-football-poll and https://apnews.com/hub/college-footballYesterday, the New Jersey Devils took to social media to announce that Jake Allen was being evaluated and might not be in the lineup for the Dec. 10 game. Today they announced that they have recalled Isaac Poulter from the Utica Comets. Per Sheldon Keefe, Jake Allen is being evaluated today and is questionable to back up Jacob Markstrom tomorrow against Toronto. Poulter has been a goalie for the Utica Comets since the 2022-23 season . In 2022-23, he played in 13 games, racking up seven wins, three losses, and three OT/shootout losses with a save percentage (SV%) of .883. During the 2023-24 season, he played in 28 games, earning 17 wins, eight losses, and one OT/shootout loss. His SV% increased to .911. He also split his time between the Adirondack Thunder in the ECHL during these two seasons. In 2022-23, Poulter played in 22 games for the Thunder, earning him a SV% of .910. He played in only six games for the Thunder in 2023-24, with a total SV% of .917. So far this season, Poulter has played in nine games for the Comets, earning two wins and four losses, as well as three OT/shootout losses. His current SV% is .871. Poulter has yet to play in an NHL game, but he took part in the optional skate for the Devils this morning. He will back up Jacob Markstrom tonight against the Toronto Maple Leafs. This article first appeared on The Hockey Writers and was syndicated with permission.CONCORD, N.H. (AP) — School district officials who punished two parents for wearing pink wristbands marked “XX” during a soccer game featuring a transgender player defended their decision Friday at a hearing on whether they can take similar action while they are being sued. Kyle Fellers and Anthony Foote were banned from school grounds after the September game by officials who viewed the wristbands as intimidation or harassment of a transgender player. They later sued the Bow school district, and while the no-trespass orders have since expired, a judge is deciding whether the plaintiffs should be allowed to wear the wristbands and carry signs at upcoming school events, including basketball games, swim meets and a music concert, while the case proceeds. Both men testified Thursday that they didn’t intend to harass or otherwise target a transgender player on the opposing team, and their attorneys have argued they did nothing more than silently express their support for reserving girls’ sports for those born female. But school officials testified Friday that they had reason to believe the men wouldn’t stop there. Superintendent Marcy Kelley and Bow High School Athletic Director Michael Desiletes described receiving strongly-worded emails from Foote in which he called himself a “real leader” who was prepared to take action and seeing his social media posts urging others to attend the game. In the days leading up to the game, another parent told school officials she overheard others talk about showing up to the game wearing dresses and heckling the transgender player. “When we suspect there’s some sort of threat ... we don’t wait for it to happen,” Kelley said, comparing it to the way school officials wouldn’t wait until a fight broke out between two students to intervene if they got wind of it beforehand. Kelley also pushed back on the idea that the plaintiffs were simply expressing support for their daughters and their teammates in general, noting that they chose the one game involving a transgender player to begin wearing the wristbands. “This was organized and targeted,” she said. “If we were to allow harassment, we’re liable.” The transgender player in question, Parker Tirrell, and another student athlete are challenging the state law that bans transgender athletes in grades 5 to 12 from teams that align with their gender identity. A federal judge ruled in their case that they can play sports during the ongoing lawsuit that seeks to overturn the law. Gov. Chris Sununu, who signed the Fairness in Women’s Sports Act into law in July, has said it “ensures fairness and safety in women’s sports by maintaining integrity and competitive balance in athletic competitions.” About half of states have adopted similar measures.

ST. PAUL — St. Paul-based Bremer Bank is being acquired by Old National Bank, which has headquarters in Evansville, Indiana, in a transaction valued at $1.4 billion in cash and stock. The deal, which still requires regulatory approval and approval by Bremer shareholders, would combine Bremer’s $16.2 billion in assets with Old National’s nearly $54 billion to create a bank with more than $70 billion in total assets. ADVERTISEMENT “This partnership represents an outstanding fit between two highly compatible, relationship- and community-focused banks,” Old National Chairman and CEO Jim Ryan said in a joint announcement released Monday, Nov. 25. Ryan said what has made Bremer Bank a leading institution since 1943 aligns closely with the “strategic priorities and cultural principles that have guided Old National’s success for 190 years: a strong deposit franchise, a diversified loan portfolio accentuated by exceptional credit quality, and a passion for investing in and strengthening communities.” “For more than 80 years, we’ve been honored to carry out the legacy of our founder, Otto Bremer,” said Jeanne Crain, president and CEO of Bremer. “When our majority shareholder, the Otto Bremer Trust, reaffirmed its interest in selling Bremer Bank, we appreciated the opportunity to identify a partner through a collaborative process to ensure the best possible outcome for our customers, employees, and our communities. With Old National, we have confidence we found a great fit,” Crain said as part of the joint announcement. The Otto Bremer Trust, a majority owner of Bremer Bank, is a private charitable trust based in St. Paul. Since the trust’s inception in 1944, it has made more than $1.1 billion in grants and program-related investments to more than 4,200 organizations. Once the merger is complete, the trust will have an approximate 11% ownership stake in Old National Bank and a trustee of the Otto Bremer Trust will join the Old National board of directors. ADVERTISEMENT The Otto Bremer Trust stated as part of the joint announcement: “All of us at the Otto Bremer Trust are excited that the Bremer Bank legacy of investing in people, places and opportunities continues with one of the most community-minded banks in the nation. This partnership expands the scope of what can be accomplished for and within our communities — civically, socially and economically.” Once the deal is finalized, Old National will become the third-largest bank in the Twin Cities, and the partnership will expand Old National’s reach into several other markets throughout Minnesota, North Dakota and Wisconsin. The deal affects 48 Bremer Bank branches in Minnesota and 14 in North Dakota, including six locations in Grand Forks and seven in the Fargo region.MD_Prather 25 pass from Morris (Howes kick), 14:46. PSU_FG Barker 49, 12:47. PSU_Singleton 2 run (Barker kick), 12:53. PSU_Allar 1 run (Barker kick), 10:11. PSU_Pribula 1 run (Barker kick), 6:53. PSU_Warren 7 pass from Allar (Barker kick), 1:46. PSU_Singleton 18 run (Barker kick), 14:14. PSU_Denmark 15 pass from Pribula, :00. RUSHING_Maryland, Hemby 13-64, Ray 9-51, C.Long 1-0, Morris 8-(minus 29). Penn St., Singleton 14-89, Allen 13-34, Warren 3-32, Smith 6-25, Allar 6-21, Pribula 5-17, Martin 2-0. PASSING_Maryland, Morris 14-24-3-112, C.Long 1-2-0-10. Penn St., Allar 16-26-0-147, Allen 1-1-0-24, Pribula 2-3-0-13, Warren 1-1-0-9. RECEIVING_Maryland, Felton 4-27, Hemby 3-20, Wade 2-17, Howard 2-12, Prather 1-25, Ray 1-10, Wisloski 1-9, Haughton 1-2. Penn St., Warren 6-68, Evans 4-49, Kh.Dinkins 3-36, Singleton 3-17, Denmark 1-15, Clifford 1-5, Fleming 1-5, Smith 1-(minus 2). MISSED FIELD GOALS_Penn St., Barker 53.